BRPI0511706A - composto ou um zwitterìon do mesmo ou um sal farmaceuticamente aceitável do mesmo, intermediário, processo de preparar um composto, método para preparar um intermediário - Google Patents

composto ou um zwitterìon do mesmo ou um sal farmaceuticamente aceitável do mesmo, intermediário, processo de preparar um composto, método para preparar um intermediário

Info

Publication number
BRPI0511706A
BRPI0511706A BRPI0511706-2A BRPI0511706A BRPI0511706A BR PI0511706 A BRPI0511706 A BR PI0511706A BR PI0511706 A BRPI0511706 A BR PI0511706A BR PI0511706 A BRPI0511706 A BR PI0511706A
Authority
BR
Brazil
Prior art keywords
preparing
compound
zwitterion
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
BRPI0511706-2A
Other languages
English (en)
Inventor
Daniel S Dickman
Dange Vijay Kumar
Colin O'bryan
Roopa Rai
William Dvorak Shrader
Kieron Wesson
Original Assignee
Pharmacyclics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Inc filed Critical Pharmacyclics Inc
Publication of BRPI0511706A publication Critical patent/BRPI0511706A/pt
Publication of BRPI0511706A8 publication Critical patent/BRPI0511706A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPOSTO OU UM ZWITTERìON DO MESMO OU UM SAL FARMACEUTICAMENTE ACEITáVEL DO MESMO, INTERMEDIáRIO, PROCESSO DE PREPARAR UM COMPOSTO, MéTODO PARA PREPARAR UM INTERMEDIáRIO A presente invenção diz respeito a novos inibidores de Fatores VIIa, IXa, Xa, XIa, em particular Fator VIIa, composições farmacêuticas que compreende estes inibidores e métodos para usar estes inibidores para tratar ou prevenir distúrbios tromboembólicos, câncer ou artrite reumatóide. Processos para preparar estes inibidores também são divulgados.
BRPI0511706A 2004-06-02 2005-06-02 composto ou um zwitteríon do mesmo ou um sal farmaceuticamente aceitável do mesmo, intermediário, processo de preparar um composto, método para preparar um intermediário BRPI0511706A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57638204P 2004-06-02 2004-06-02
PCT/US2005/019394 WO2005118554A2 (en) 2004-06-02 2005-06-02 Factor viia inhibitor

Publications (2)

Publication Number Publication Date
BRPI0511706A true BRPI0511706A (pt) 2008-01-08
BRPI0511706A8 BRPI0511706A8 (pt) 2018-12-11

Family

ID=35124622

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511706A BRPI0511706A8 (pt) 2004-06-02 2005-06-02 composto ou um zwitteríon do mesmo ou um sal farmaceuticamente aceitável do mesmo, intermediário, processo de preparar um composto, método para preparar um intermediário

Country Status (13)

Country Link
US (2) US20080275250A1 (pt)
EP (1) EP1761504A2 (pt)
JP (1) JP2008501700A (pt)
KR (1) KR100977903B1 (pt)
CN (2) CN102417484A (pt)
AU (1) AU2005250470B2 (pt)
BR (1) BRPI0511706A8 (pt)
CA (1) CA2569163A1 (pt)
IL (1) IL179670A (pt)
MX (1) MXPA06014071A (pt)
NZ (1) NZ551728A (pt)
WO (1) WO2005118554A2 (pt)
ZA (1) ZA200610573B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1569912B1 (en) 2002-12-03 2015-04-29 Pharmacyclics, Inc. 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
CN102417484A (zh) 2004-06-02 2012-04-18 法莫西克立克斯公司 因子VIIa抑制剂
US8729117B2 (en) 2004-06-02 2014-05-20 Pharmacyclics, Inc. Factor VIIa inhibitor
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP2586794A3 (en) 2007-10-16 2013-07-17 Pharmacyclics, Inc. Manufacture, Compositions and Uses of Coagulationfactor VIIA Modulator
WO2010085462A1 (en) 2009-01-22 2010-07-29 Merck Patent Gmbh Method for treating triple negative breast cancer
EP2906236A1 (en) * 2012-10-10 2015-08-19 Novo Nordisk Health Care AG Liquid pharmaceutical composition of factor vii polypeptide

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002532479A (ja) * 1998-12-18 2002-10-02 アクシス・ファーマシューティカルズ・インコーポレイテッド プロテアーゼインヒビター
US20020037912A1 (en) 2000-08-11 2002-03-28 Leahy Ellen M. Factor viia inhibitors
US6465503B2 (en) 2000-08-11 2002-10-15 Axys Pharmaceuticals, Inc. Selective urokinase inhibitors
EP1408963A1 (en) 2001-07-09 2004-04-21 Axys Pharmaceuticals, Inc. 2- 5-(5-CARBAMIMIDOYL-1 i H /i -HETEROARYL)-6-HYDROXYBIPHENYL-3-YL]-SUCCINIC ACID DERIVATIVES AS FACTOR VIIA INHIBITORS
EP1281700A1 (en) * 2001-07-31 2003-02-05 Resolution Research Nederland B.V. Manufacturing process for the preparation of alpha, alpha-branched alkane carboxylic acids providing esters with an improved softness
EP1569912B1 (en) 2002-12-03 2015-04-29 Pharmacyclics, Inc. 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
AU2003215158A1 (en) * 2002-02-13 2003-09-04 Axys Pharmaceuticals, Inc. 2-(5-(5-carbamimidoyl-1h-heteroaryl))-6-hydroxybiphenyl-3-yl derivatives as factor viia inhibitors
WO2004062661A1 (en) 2003-01-08 2004-07-29 Axys Pharmaceuticals, Inc. 2-‘5-(5-carbamimidoyl-1h-heteroaryl)-6-hydroxybiphenyl-3-yl!- carboxylic acid derivatives as factor viia inhibitors
CN102417484A (zh) 2004-06-02 2012-04-18 法莫西克立克斯公司 因子VIIa抑制剂
CN1976903A (zh) 2004-06-02 2007-06-06 法莫西克立克斯公司 因子VⅡa抑制剂
EP2586794A3 (en) 2007-10-16 2013-07-17 Pharmacyclics, Inc. Manufacture, Compositions and Uses of Coagulationfactor VIIA Modulator

Also Published As

Publication number Publication date
WO2005118554A2 (en) 2005-12-15
US20110207939A1 (en) 2011-08-25
JP2008501700A (ja) 2008-01-24
WO2005118554A3 (en) 2006-05-18
ZA200610573B (en) 2008-06-25
IL179670A0 (en) 2007-05-15
CN102417484A (zh) 2012-04-18
KR100977903B1 (ko) 2010-08-24
AU2005250470A1 (en) 2005-12-15
BRPI0511706A8 (pt) 2018-12-11
KR20070040781A (ko) 2007-04-17
EP1761504A2 (en) 2007-03-14
AU2005250470B2 (en) 2008-03-06
CA2569163A1 (en) 2005-12-15
MXPA06014071A (es) 2007-02-15
NZ551728A (en) 2010-03-26
IL179670A (en) 2013-10-31
US20080275250A1 (en) 2008-11-06
US8415328B2 (en) 2013-04-09
CN1964951A (zh) 2007-05-16

Similar Documents

Publication Publication Date Title
MX2009013565A (es) Derivados de azapeptidos.
NO20083918L (no) Dihydridiazepiner anvendelige som inhibitorer av proteinkinaser
NO20085004L (no) Radioaktivt merkede dihydrotetrabenazinderivater og deres anvendelse som avbildningsmidler
UA96126C2 (ru) Соединение для ингибирования активности rho киназы, фармацевтическая композиция, которая содержит такое соединение, и способ ингибирования активности rho киназы
WO2006132914A3 (en) Cyclobutyl amine derivatives
WO2007098099A3 (en) Method of treating a subject suffering from degenerative disc disease using a matrix metalloprotease inhibitor
BRPI0715746B8 (pt) composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica os compreendendo
NO20053972L (no) Aminosyre-avledede prodrug av propofol, sammensetninger og anvendelse derav.
BRPI0507903A (pt) derivados de quinazolina e composição farmacêutica compreendendo os mesmos
NO20083836L (no) N-hydroksyakrylamidforbindelser
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
BRPI0518647A2 (pt) processo para a produÇço de um composto, e, composto
DK1648484T3 (da) Fremgangsmåde til behandling af arthritis-tilstande
WO2005084654A3 (en) Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
NO20076186L (no) Mitotiske kinesininhibitorer og fremgangsmater for anvendelse derav
BRPI0512705A (pt) composto, processo de preparação deste e método para o tratamento e profilaxia de diabetes, obesidade, distúrbios alimentares, dilipidemia, hipertensão e diabetes do tipo ii
BRPI0511706A (pt) composto ou um zwitterìon do mesmo ou um sal farmaceuticamente aceitável do mesmo, intermediário, processo de preparar um composto, método para preparar um intermediário
BRPI0607792A2 (pt) processo para a preparação de moduladores de opióides
BRPI0410837A (pt) composto, composição farmacêutica, e, método para tratar ou prevenir uma doença ou condição
BRPI0508969A (pt) compostos orgánicos
MY146028A (en) Benzothiazole cyclobutyl amine derivatives
BRPI0511714A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para tratar uma doença em um animal
BRPI0517032A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e utilização desses compostos
BRPI0414200A (pt) processos para a preparação do composto, para a produção e preparação de renzapride e para a produção de hidrocloreto de renzapride, composto, processos para a formação do composto e para a preparação de ácido, da amina e do sal de hidrocloreto do composto, composição farmacêutica, e, método para tratamento de desordem relacionada à motilidade gastrintestinal prejudicada
BRPI0606639A2 (pt) novo processo para a preparação de indóis substituìdos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08G Application fees: restoration [chapter 8.7 patent gazette]
B25A Requested transfer of rights approved

Owner name: OXFORD AMHERST LLC (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: PHARMACYCLICS LLC (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time